Floatz logo

FULVESTRANT

FGFR2 Amplification

Taiho Oncology, Inc.Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the FGFR2 Amplification cohort.

Asset / SponsorPhaseRating
Lirafugratinib
Elevar Therapeutics
Phase 1/2CCC
Futibatinib
Taiho Oncology, Inc.
Phase 2CCC

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant
BB
Indicative ·
70 / 100
View asset →
hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Progesterone Receptor PositiveDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →